Search

Your search keyword '"Lyke, Kirsten E"' showing total 350 results
Start Over Author "Lyke, Kirsten E"
350 results on '"Lyke, Kirsten E"'

1. Repeat controlled human Plasmodium falciparum infections delay bloodstream patency and reduce symptoms

Author

Ferrer, Patricia, Berry, Andrea A., Bucsan, Allison N., Prajapati, Surendra K., Krishnan, Karthik, Barbeau, Michelle C., Rickert, David M., Guerrero, Sandra Mendoza, Usui, Miho, Abebe, Yonas, Patil, Asha, Chakravarty, Sumana, Billingsley, Peter F., Pa’ahana-Brown, Faith, Strauss, Kathy, Shrestha, Biraj, Nomicos, Effie, Deye, Gregory A., Sim, B. Kim Lee, Hoffman, Stephen L., Williamson, Kim C., and Lyke, Kirsten E.

Published
2024
Full Text
View/download PDF

2. Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials

Author

Happe, Myra, Hofstetter, Amelia R., Wang, Jing, Yamshchikov, Galina V., Holman, LaSonji A., Novik, Laura, Strom, Larisa, Kiweewa, Francis, Wakabi, Salim, Millard, Monica, Kelley, Colleen F., Kabbani, Sarah, Edupuganti, Srilatha, Beck, Allison, Kaltovich, Florence, Murray, Tamar, Tsukerman, Susanna, Carr, Derick, Ashman, Carl, Stanley, Daphne A., Ploquin, Aurélie, Bailer, Robert T., Schwartz, Richard, Cham, Fatim, Tindikahwa, Allan, Hu, Zonghui, Gordon, Ingelise J., Rouphael, Nadine, Houser, Katherine V., Coates, Emily E., Graham, Barney S., Koup, Richard A., Mascola, John R., Sullivan, Nancy J., Robb, Merlin L., Ake, Julie A., Lyke, Kirsten E., Mulligan, Mark J., Ledgerwood, Julie E., and Kibuuka, Hannah

Published
2024
Full Text
View/download PDF

3. Gene expression analyses reveal differences in children’s response to malaria according to their age

Author

Tebben, Kieran, Yirampo, Salif, Coulibaly, Drissa, Koné, Abdoulaye K., Laurens, Matthew B., Stucke, Emily M., Dembélé, Ahmadou, Tolo, Youssouf, Traoré, Karim, Niangaly, Amadou, Berry, Andrea A., Kouriba, Bourema, Plowe, Christopher V., Doumbo, Ogobara K., Lyke, Kirsten E., Takala-Harrison, Shannon, Thera, Mahamadou A., Travassos, Mark A., and Serre, David

Published
2024
Full Text
View/download PDF

4. Children with hemoglobin C or S trait have low serologic responses to a subset of malaria variant surface antigens

Author

Bailey, Rachel D., Lawton, Jonathan G., Niangaly, Amadou, Stucke, Emily M., Bailey, Jason A., Berry, Andrea A., Ouattara, Amed, Coulibaly, Drissa, Lyke, Kirsten E., Laurens, Matthew B., Zhou, Albert E., Pablo, Jozelyn, Jasinskas, Algis, Nakajima, Rie, Adams, Matthew, Takala-Harrison, Shannon, Kouriba, Bourema, Kone, Abdoulaye K., Guindo, Aldiouma, Rowe, J. Alexandra, Diallo, Dapa A., Doumbo, Ogobara K., Felgner, Philip L., Plowe, Christopher V., Thera, Mahamadou A., and Travassos, Mark A.

Published
2024
Full Text
View/download PDF

5. Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial

Author

Lyke, Kirsten E, Chua, Joel V, Koren, Michael, Friberg, Heather, Gromowski, Gregory D, Rapaka, Rekha R, Waickman, Adam T, Joshi, Sudhaunshu, Strauss, Kathleen, McCracken, Michael K, Gutierrez-Barbosa, Hernando, Shrestha, Biraj, Culbertson, Christopher, Bernal, Paula, De La Barrera, Rafael A, Currier, Jeffrey R, Jarman, Richard G, and Edelman, Robert

Published
2024
Full Text
View/download PDF

6. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

Author

Branche, Angela R., Rouphael, Nadine G., Diemert, David J., Falsey, Ann R., Losada, Cecilia, Baden, Lindsey R., Frey, Sharon E., Whitaker, Jennifer A., Little, Susan J., Anderson, Evan J., Walter, Emmanuel B., Novak, Richard M., Rupp, Richard, Jackson, Lisa A., Babu, Tara M., Kottkamp, Angelica C., Luetkemeyer, Anne F., Immergluck, Lilly C., Presti, Rachel M., Bäcker, Martín, Winokur, Patricia L., Mahgoub, Siham M., Goepfert, Paul A., Fusco, Dahlene N., Malkin, Elissa, Bethony, Jeffrey M., Walsh, Edward E., Graciaa, Daniel S., Samaha, Hady, Sherman, Amy C., Walsh, Stephen R., Abate, Getahun, Oikonomopoulou, Zacharoula, El Sahly, Hana M., Martin, Thomas C. S., Kamidani, Satoshi, Smith, Michael J., Ladner, Benjamin G., Porterfield, Laura, Dunstan, Maya, Wald, Anna, Davis, Tamia, Atmar, Robert L., Mulligan, Mark J., Lyke, Kirsten E., Posavad, Christine M., Meagher, Megan A., Stephens, David S., Neuzil, Kathleen M., Abebe, Kuleni, Hill, Heather, Albert, Jim, Telu, Kalyani, Mu, Jinjian, Lewis, Teri C., Giebeig, Lisa A., Eaton, Amanda, Netzl, Antonia, Wilks, Samuel H., Türeli, Sina, Makhene, Mamodikoe, Crandon, Sonja, Montefiori, David C., Makowski, Mat, Smith, Derek J., Nayak, Seema U., Roberts, Paul C., and Beigel, John H.

Published
2023
Full Text
View/download PDF

7. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants

Author

Lyke, Kirsten E., Atmar, Robert L., Dominguez Islas, Clara, Posavad, Christine M., Deming, Meagan E., Branche, Angela R., Johnston, Christine, El Sahly, Hana M., Edupuganti, Srilatha, Mulligan, Mark J., Jackson, Lisa A., Rupp, Richard E., Rostad, Christina A., Coler, Rhea N., Bäcker, Martín, Kottkamp, Angelica C., Babu, Tara M., Dobrzynski, David, Martin, Judith M., Brady, Rebecca C., Frenck, Jr., Robert W., Rajakumar, Kumaravel, Kotloff, Karen, Rouphael, Nadine, Szydlo, Daniel, PaulChoudhury, Rahul, Archer, Janet I., Crandon, Sonja, Ingersoll, Brian, Eaton, Amanda, Brown, Elizabeth R., McElrath, M. Juliana, Neuzil, Kathleen M., Stephens, David S., Post, Diane J., Lin, Bob C., Serebryannyy, Leonid, Beigel, John H., Montefiori, David C., and Roberts, Paul C.

Published
2023
Full Text
View/download PDF

8. Repeated Plasmodium falciparum infection in humans drives the clonal expansion of an adaptive γδ T cell repertoire

Author

von Borstel, Anouk, Chevour, Priyanka, Arsovski, Daniel, Krol, Jelte MM, Howson, Lauren J, Berry, Andrea A, Day, Cheryl L, Ogongo, Paul, Ernst, Joel D, Nomicos, Effie YH, Boddey, Justin A, Giles, Edward M, Rossjohn, Jamie, Traore, Boubacar, Lyke, Kirsten E, Williamson, Kim C, Crompton, Peter D, and Davey, Martin S

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Immunology, Vector-Borne Diseases, Rare Diseases, Infectious Diseases, Clinical Research, Malaria, Aetiology, 2.1 Biological and endogenous factors, Infection, Good Health and Well Being, Adult, Australia, Child, Humans, Malaria, Falciparum, Plasmodium falciparum, Receptors, Antigen, T-Cell, gamma-delta, T-Lymphocytes, Biological Sciences, Medical and Health Sciences, Medical biotechnology, Biomedical engineering
Abstract

Repeated Plasmodium falciparum infections drive the development of clinical immunity to malaria in humans; however, the immunological mechanisms that underpin this response are only partially understood. We investigated the impact of repeated P. falciparum infections on human γδ T cells in the context of natural infection in Malian children and adults, as well as serial controlled human malaria infection (CHMI) of U.S. adults, some of whom became clinically immune to malaria. In contrast to the predominant Vδ2+ T cell population in malaria-naïve Australian individuals, clonally expanded cytotoxic Vδ1effector T cells were enriched in the γδ T cell compartment of Malian subjects. Malaria-naïve U.S. adults exposed to four sequential CHMIs defined the precise impact of P. falciparum on the γδ T cell repertoire. Specifically, innate-like Vδ2+ T cells exhibited an initial robust polyclonal response to P. falciparum infection that was not sustained with repeated infections, whereas Vδ1+ T cells increased in frequency with repeated infections. Moreover, repeated P. falciparum infection drove waves of clonal selection in the Vδ1+ T cell receptor repertoire that coincided with the differentiation of Vδ1naïve T cells into cytotoxic Vδ1effector T cells. Vδ1+ T cells of malaria-exposed Malian and U.S. individuals were licensed for reactivity to P. falciparum parasites in vitro. Together, our study indicates that repeated P. falciparum infection drives the clonal expansion of an adaptive γδ T cell repertoire and establishes a role for Vδ1+ T cells in the human immune response to malaria.

Published
2021

9. Immunoprofiles associated with controlled human malaria infection and naturally acquired immunity identify a shared IgA pre-erythrocytic immunoproteome

Author

Berry, Andrea A, Obiero, Joshua M, Travassos, Mark A, Ouattara, Amed, Coulibaly, Drissa, Adams, Matthew, de Assis, Rafael Ramiro, Jain, Aarti, Taghavian, Omid, Sy, Andrew, Nakajima, Rie, Jasinskas, Algis, Laurens, Matthew B, Takala-Harrison, Shannon, Kouriba, Bourema, Kone, Abdoulaye K, Doumbo, Ogobara K, Sim, B Kim Lee, Hoffman, Stephen L, Plowe, Christopher V, Thera, Mahamadou A, Felgner, Philip L, and Lyke, Kirsten E

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Rare Diseases, Clinical Research, Malaria, HIV/AIDS, Infectious Diseases, Biotechnology, Immunization, Vector-Borne Diseases, Pediatric, Aetiology, 2.1 Biological and endogenous factors, Infection, Good Health and Well Being, Immunology, Medical microbiology
Abstract

Knowledge of the Plasmodium falciparum antigens that comprise the human liver stage immunoproteome is important for pre-erythrocytic vaccine development, but, compared with the erythrocytic stage immunoproteome, more challenging to classify. Previous studies of P. falciparum antibody responses report IgG and rarely IgA responses. We assessed IgG and IgA antibody responses in adult sera collected during two controlled human malaria infection (CHMI) studies in malaria-naïve volunteers and in 1- to 6-year-old malaria-exposed Malian children on a 251 P. falciparum antigen protein microarray. IgG profiles in the two CHMI groups were equivalent and differed from Malian children. IgA profiles were robust in the CHMI groups and a subset of Malian children. We describe immunoproteome differences in naïve vs. exposed individuals and report pre-erythrocytic proteins recognized by the immune system. IgA responses detected in this study expand the list of pre-erythrocytic antigens for further characterization as potential vaccine candidates.

Published
2021

10. Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial

Author

Young, Cheryl, Boyce, Colleen, Winkler, Jennifer, Holian, Susan, Greenberg, Nancy, George, Shirley, Kwon, Alyson, Dorsey, Brenda, Da Costa, Ana Raquel, Witt, William, Grays, Daryl, Gapasin, Arren, Bernal, Paula, Floyd, Jeffrey, Goldstein, Eric, Howe, Leslie, Lee, Myounghee, Marron, Jennifer, Brooks, Kelly, Turek, Lisa, Farley, Patricia, Frels, Shantel, Booth, Delores, Gall, Jason, Carlton, Kevin, Albright, Gabriela, Amharref, Nadia, Atallah, Kandace, Banappagari, Sashikanth, Bastani, Niutish, Blackstock, Daniel, Boonyaratanakornkit, Bobby, Carey, Elizabeth, Charlton, Adam, Chaudhuri, Rajoshi, Caringal, Alegria M., Chen, Mingzhong, Chen, Peifeng, Cheng, Wei, Gowetski, Daniel, Gulla, Krishana, Hastings, Erica, Horwitz, Joe, Ivleva, Vera, Kordella, Dan, Kueltzo, Lisa A., Lagler, Sara, Le, Matt, Lee, James, Lei, Paula, Li, Yile, Nagy, Attila, Patel, Aakash, Runsewe, Peyi, Shadrick, Will, Shetty, Shamitha, Wang, Hairong, Webber, Calvin, Vejzagic, Farah, Yang, Yoo-Jung, Lyke, Kirsten E, Berry, Andrea A, Mason, Kaitlin, Idris, Azza H, O'Callahan, Mark, Happe, Myra, Strom, Larisa, Berkowitz, Nina M, Guech, Mercy, Hu, Zonghui, Castro, Mike, Basappa, Manjula, Wang, Lu, Low, Kwang, Holman, LaSonji A, Mendoza, Floreliz, Gordon, Ingelise J, Plummer, Sarah H, Trofymenko, Olga, Strauss, Kathleen S, Joshi, Sudhaunshu, Shrestha, Biraj, Adams, Matthew, Chagas, Andrezza Campos, Murphy, Jittawadee R, Stein, Judy, Hickman, Somia, McDougal, Andrew, Lin, Bob, Narpala, Sandeep R, Vazquez, Sandra, Serebryannyy, Leonid, McDermott, Adrian, Gaudinski, Martin R, Capparelli, Edmund V, Coates, Emily E, Wu, Richard L, Ledgerwood, Julie E, Dropulic, Lesia K, and Seder, Robert A

Published
2023
Full Text
View/download PDF

11. Microarray analyses reveal strain-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 variants following natural infection and vaccination

Author

Bailey, Jason A, Berry, Andrea A, Travassos, Mark A, Ouattara, Amed, Boudova, Sarah, Dotsey, Emmanuel Y, Pike, Andrew, Jacob, Christopher G, Adams, Matthew, Tan, John C, Bannen, Ryan M, Patel, Jigar J, Pablo, Jozelyn, Nakajima, Rie, Jasinskas, Algis, Dutta, Sheetij, Takala-Harrison, Shannon, Lyke, Kirsten E, Laurens, Matthew B, Niangaly, Amadou, Coulibaly, Drissa, Kouriba, Bourema, Doumbo, Ogobara K, Thera, Mahamadou A, Felgner, Philip L, and Plowe, Christopher V

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Biotechnology, Malaria, Vector-Borne Diseases, Immunization, Infectious Diseases, Rare Diseases, HIV/AIDS, Vaccine Related, Prevention of disease and conditions, and promotion of well-being, 3.4 Vaccines, Infection, Good Health and Well Being, Antibodies, Protozoan, Antibody Formation, Antigens, Protozoan, Malaria Vaccines, Malaria, Falciparum, Membrane Proteins, Plasmodium falciparum, Protozoan Proteins
Abstract

Vaccines based on Plasmodium falciparum apical membrane antigen 1 (AMA1) have failed due to extensive polymorphism in AMA1. To assess the strain-specificity of antibody responses to malaria infection and AMA1 vaccination, we designed protein and peptide microarrays representing hundreds of unique AMA1 variants. Following clinical malaria episodes, children had short-lived, sequence-independent increases in average whole-protein seroreactivity, as well as strain-specific responses to peptides representing diverse epitopes. Vaccination resulted in dramatically increased seroreactivity to all 263 AMA1 whole-protein variants. High-density peptide analysis revealed that vaccinated children had increases in seroreactivity to four distinct epitopes that exceeded responses to natural infection. A single amino acid change was critical to seroreactivity to peptides in a region of AMA1 associated with strain-specific vaccine efficacy. Antibody measurements using whole antigens may be biased towards conserved, immunodominant epitopes. Peptide microarrays may help to identify immunogenic epitopes, define correlates of vaccine protection, and measure strain-specific vaccine-induced antibodies.

Published
2020

12. Serologic responses to the PfEMP1 DBL-CIDR head structure may be a better indicator of malaria exposure than those to the DBL-α tag

Author

Stucke, Emily M, Niangaly, Amadou, Berry, Andrea A, Bailey, Jason A, Coulibaly, Drissa, Ouattara, Amed, Lyke, Kirsten E, Laurens, Matthew B, Dara, Antoine, Adams, Matthew, Pablo, Jozelyn, Jasinskas, Algis, Nakajima, Rie, Zhou, Albert E, Agrawal, Sonia, Friedman-Klabanoff, DeAnna J, Takala-Harrison, Shannon, Kouriba, Bourema, Kone, Abdoulaye K, Rowe, J Alexandra, Doumbo, Ogobara K, Felgner, Philip L, Thera, Mahamadou A, Plowe, Christopher V, and Travassos, Mark A

Subjects
Clinical Research, HIV/AIDS, Malaria, Infectious Diseases, Pediatric, Rare Diseases, Vector-Borne Diseases, Infection, Good Health and Well Being, Adult, Antigens, Protozoan, Child, Child, Preschool, Conserved Sequence, Humans, Infant, Malaria, Falciparum, Middle Aged, Plasmodium falciparum, Protein Structure, Tertiary, Protozoan Proteins, Young Adult, var genes, PfEMP1, Immunity, Seroreactivity, Microarray, Microbiology, Medical Microbiology, Public Health and Health Services, Tropical Medicine
Abstract

BackgroundPlasmodium falciparum erythrocyte membrane protein-1 (PfEMP1) antigens play a critical role in host immune evasion. Serologic responses to these antigens have been associated with protection from clinical malaria, suggesting that antibodies to PfEMP1 antigens may contribute to natural immunity. The first N-terminal constitutive domain in a PfEMP1 is the Duffy binding-like alpha (DBL-α) domain, which contains a 300 to 400 base pair region unique to each particular protein (the DBL-α "tag"). This DBL-α tag has been used as a marker of PfEMP1 diversity and serologic responses in malaria-exposed populations. In this study, using sera from a malaria-endemic region, responses to DBL-α tags were compared to responses to the corresponding entire DBL-α domain (or "parent" domain) coupled with the succeeding cysteine-rich interdomain region (CIDR).MethodsA protein microarray populated with DBL-α tags, the parent DBL-CIDR head structures, and downstream PfEMP1 protein fragments was probed with sera from Malian children (aged 1 to 6 years) and adults from the control arms of apical membrane antigen 1 (AMA1) vaccine clinical trials before and during a malaria transmission season. Serological responses to the DBL-α tag and the DBL-CIDR head structure were measured and compared in children and adults, and throughout the season.ResultsMalian serologic responses to a PfEMP1's DBL-α tag region did not correlate with seasonal malaria exposure, or with responses to the parent DBL-CIDR head structure in either children or adults. Parent DBL-CIDR head structures were better indicators of malaria exposure.ConclusionsLarger PfEMP1 domains may be better indicators of malaria exposure than short, variable PfEMP1 fragments such as DBL-α tags. PfEMP1 head structures that include conserved sequences appear particularly well suited for study as serologic predictors of malaria exposure.

Published
2019

13. Antibodies to Peptides in Semiconserved Domains of RIFINs and STEVORs Correlate with Malaria Exposure

Author

Zhou, Albert E, Berry, Andrea A, Bailey, Jason A, Pike, Andrew, Dara, Antoine, Agrawal, Sonia, Stucke, Emily M, Ouattara, Amed, Coulibaly, Drissa, Lyke, Kirsten E, Laurens, Matthew B, Adams, Matthew, Takala-Harrison, Shannon, Pablo, Jozelyn, Jasinskas, Algis, Nakajima, Rie, Niangaly, Amadou, Kouriba, Bourema, Kone, Abdoulaye K, Rowe, J Alexandra, Doumbo, Ogobara K, Thera, Mahamadou A, Patel, Jigar J, Tan, John C, Felgner, Philip L, Plowe, Christopher V, and Travassos, Mark A

Subjects
Infectious Diseases, Pediatric, Clinical Research, Rare Diseases, Malaria, Vector-Borne Diseases, 2.1 Biological and endogenous factors, Aetiology, Infection, Good Health and Well Being, Adolescent, Adult, Age Factors, Antibodies, Protozoan, Antigens, Protozoan, Child, Child, Preschool, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Endemic Diseases, Female, Humans, Immunity, Innate, Infant, Interspersed Repetitive Sequences, Male, Mali, Middle Aged, Peptides, Plasmodium falciparum, Protein Array Analysis, Young Adult, RIFIN, STEVOR, malaria, microarrays, peptide, semiconserved domain, severe malaria, variant surface antigen, Plasmodium falciparum, Immunology, Microbiology
Abstract

The repetitive interspersed family (RIFIN) and the subtelomeric variable open reading frame (STEVOR) family represent two of three major Plasmodium falciparum variant surface antigen families involved in malaria pathogenesis and immune evasion and are potential targets in the development of natural immunity. Protein and peptide microarrays populated with RIFINs and STEVORs associated with severe malaria vulnerability in Malian children were probed with adult and pediatric sera to identify epitopes that reflect malaria exposure. Adult sera recognized and reacted with greater intensity to all STEVOR proteins than pediatric sera did. Serorecognition of and seroreactivity to peptides within the semiconserved domain of STEVORs increased with age and seasonal malaria exposure, while serorecognition and seroreactivity increased for the semiconserved and second hypervariable domains of RIFINs only with age. Serologic responses to RIFIN and STEVOR peptides within the semiconserved domains may play a role in natural immunity to severe malaria.IMPORTANCE Malaria, an infectious disease caused by the parasite Plasmodium falciparum, causes nearly 435,000 deaths annually worldwide. RIFINs and STEVORs are two variant surface antigen families that are involved in malaria pathogenesis and immune evasion. Recent work has shown that a lack of humoral immunity to these proteins is associated with severe malaria vulnerability in Malian children. This is the first study to have compared serologic responses of children and adults to RIFINs and STEVORs in settings of malaria endemicity and to examine such serologic responses before and after a clinical malaria episode. Using microarrays, we determined that the semiconserved domains in these two parasite variant surface antigen families harbor peptides whose seroreactivity reflects malaria exposure. A similar approach has the potential to illuminate the role of variant surface antigens in the development of natural immunity to clinical malaria. Potential vaccines for severe malaria should include consideration of peptides within the semiconserved domains of RIFINs and STEVORs.

Published
2019

14. PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial

Author

Coulibaly, Drissa, Kone, Abdoulaye K., Traore, Karim, Niangaly, Amadou, Kouriba, Bourema, Arama, Charles, Zeguime, Amatigue, Dolo, Amagana, Lyke, Kirsten E., Plowe, Christopher V., Abebe, Yonas, Potter, Gail E., Kennedy, Jessie K., Galbiati, Shirley M., Nomicos, Effie, Deye, Gregory A., Richie, Thomas L., James, Eric R., KC, Natasha, Sim, B. Kim Lee, Hoffman, Stephen L., Doumbo, Ogobara K., Thera, Mahamadou A., and Laurens, Matthew B.

Published
2022
Full Text
View/download PDF

17. Children with cerebral malaria or severe malarial anaemia lack immunity to distinct variant surface antigen subsets

Author

Travassos, Mark A, Niangaly, Amadou, Bailey, Jason A, Ouattara, Amed, Coulibaly, Drissa, Lyke, Kirsten E, Laurens, Matthew B, Pablo, Jozelyn, Jasinskas, Algis, Nakajima, Rie, Berry, Andrea A, Adams, Matthew, Jacob, Christopher G, Pike, Andrew, Takala-Harrison, Shannon, Liang, Li, Kouriba, Bourema, Kone, Abdoulaye K, Rowe, J Alexandra, Moulds, JoAnn, Diallo, Dapa A, Doumbo, Ogobara K, Thera, Mahamadou A, Felgner, Philip L, and Plowe, Christopher V

Subjects
Malaria, Pediatric, Brain Disorders, Rare Diseases, Infectious Diseases, Vector-Borne Diseases, Clinical Research, Aetiology, 2.1 Biological and endogenous factors, Infection, Good Health and Well Being, Anemia, Antigens, Protozoan, Case-Control Studies, Child, Preschool, Female, Humans, Infant, Malaria, Cerebral, Malaria, Falciparum, Male, Plasmodium falciparum
Abstract

Variant surface antigens (VSAs) play a critical role in severe malaria pathogenesis. Defining gaps, or "lacunae", in immunity to these Plasmodium falciparum antigens in children with severe malaria would improve our understanding of vulnerability to severe malaria and how protective immunity develops. Using a protein microarray with 179 antigen variants from three VSA families as well as more than 300 variants of three other blood stage P. falciparum antigens, reactivity was measured in sera from Malian children with cerebral malaria or severe malarial anaemia and age-matched controls. Sera from children with severe malaria recognized fewer extracellular PfEMP1 fragments and were less reactive to specific fragments compared to controls. Following recovery from severe malaria, convalescent sera had increased reactivity to certain non-CD36 binding PfEMP1s, but not other malaria antigens. Sera from children with severe malarial anaemia reacted to fewer VSAs than did sera from children with cerebral malaria, and both of these groups had lacunae in their seroreactivity profiles in common with children who had both cerebral malaria and severe malarial anaemia. This microarray-based approach may identify a subset of VSAs that could inform the development of a vaccine to prevent severe disease or a diagnostic test to predict at-risk children.

Published
2018

19. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Author

Mulligan, Mark J., Lyke, Kirsten E., Kitchin, Nicholas, Absalon, Judith, Gurtman, Alejandra, Lockhart, Stephen, and Neuzil, Kathleen

Subjects
Clinical trials -- Forecasts and trends, Market trend/market analysis, Environmental issues, Science and technology, Zoology and wildlife conservation, Comirnaty (Vaccine) -- Dosage and administration -- Testing
Abstract

In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).sup.1, a pandemic. With rapidly accumulating numbers of cases and deaths reported globally.sup.2, a vaccine is urgently needed. Here we report the available safety, tolerability and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose-escalation study (ClinicalTrials.gov identifier NCT04368728) among 45 healthy adults (18-55 years of age), who were randomized to receive 2 doses--separated by 21 days--of 10 [mu]g, 30 [mu]g or 100 [mu]g of BNT162b1. BNT162b1 is a lipid-nanoparticle-formulated, nucleoside-modified mRNA vaccine that encodes the trimerized receptor-binding domain (RBD) of the spike glycoprotein of SARS-CoV-2. Local reactions and systemic events were dose-dependent, generally mild to moderate, and transient. A second vaccination with 100 [mu]g was not administered because of the increased reactogenicity and a lack of meaningfully increased immunogenicity after a single dose compared with the 30-[mu]g dose. RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second dose. Geometric mean neutralizing titres reached 1.9-4.6-fold that of a panel of COVID-19 convalescent human sera, which were obtained at least 14 days after a positive SARS-CoV-2 PCR. These results support further evaluation of this mRNA vaccine candidate. In a dose-escalation study of the COVID-19 RNA vaccine BNT162b1 in 45 healthy adults, RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second vaccine dose., Author(s): Mark J. Mulligan [sup.1] [sup.2] , Kirsten E. Lyke [sup.3] , Nicholas Kitchin [sup.4] , Judith Absalon [sup.5] , Alejandra Gurtman [sup.5] , Stephen Lockhart [sup.4] , Kathleen Neuzil [...]

Published
2020
Full Text
View/download PDF

20. Gene expression analyses reveal differences in children's response to malaria according to their age

Author

Tebben, Kieran, primary, Yirampo, Salif, additional, Coulibaly, Drissa, additional, Kone, Abdoulaye Kassoum, additional, Laurens, Matthew B., additional, Stucke, Emily, additional, Dembele, Amadou, additional, Tolo, Youssouf, additional, Traore, Karim, additional, Niangaly, Amadou, additional, Berry, Andrea A., additional, Kouriba, Bourema, additional, Plowe, Christopher V, additional, Lyke, Kirsten E., additional, Takala-Harrison, Shannon, additional, Travassos, Mark A., additional, and Serre, David, additional

Published
2023
Full Text
View/download PDF

21. Natural immunity to malaria preferentially targets the endothelial protein C receptor-binding regions of PfEMP1s

Author

Tewey, Madison A., primary, Coulibaly, Drissa, additional, Lawton, Jonathan G., additional, Stucke, Emily M., additional, Zhou, Albert E., additional, Berry, Andrea A., additional, Bailey, Jason A., additional, Pike, Andrew, additional, Dara, Antoine, additional, Ouattara, Amed, additional, Lyke, Kirsten E., additional, Ifeonu, Olukemi, additional, Laurens, Matthew B., additional, Adams, Matthew, additional, Takala-Harrison, Shannon, additional, Niangaly, Amadou, additional, Kouriba, Bourema, additional, Koné, Abdoulaye K., additional, Rowe, J. Alexandra, additional, Doumbo, Ogobara K., additional, Patel, Jigar J., additional, Tan, John C., additional, Felgner, Philip L., additional, Plowe, Christopher V., additional, Thera, Mahamadou A., additional, and Travassos, Mark A., additional

Published
2023
Full Text
View/download PDF

22. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

Author

Plummer, Sarah, Costner, Pamela, Zephir, Kathryn, Casazza, Joseph, Ola, Abidemi, Victorino, Milalynn, Levinson, Carol, Whalen, William, Wang, Xiaolin, Cunningham, Jennifer, Vasilenko, Olga, Burgos Florez, Maria, Hickman, Somia, Pittman, Iris, Le, Lam, Larkin, Brenda, Andrews, Charla, Apte, Preeti, Hicks, Renunda, Trelles Cartagena, Cora, Williams, Pernell, Boyd, Catina R, Conan-Cibotti, Michelle, Stein, Judy, Kaltovich, Florence, DeCederfelt, Hope, McAdams, Stacey, Renehan, Phyllis, Chen, Wilbur, Greenberg, Nancy, Wymer, Nancy, Wadsworth, Linda, Billington, Melissa, Robinson, Toni, Boyce, Colleen, Pa'ahana Brown, Faith, Chrisley, Lisa, Kwon, Alyson, Patel, Prashant, Kominou, Panagoita, Dorsey, Brenda, Eddington, Staci, Telscher, Shinyi, Lee, Myoughee, Mosely, Regina, Ross, April, Ford, Geoffrey, Domjahn, Briyana, Xu, Jianguo, Beck, Allison, Fineman, Rebecca, Heeke, Shiela, Winter, Jean, Nagar, Shashi, Kelley, Colleen, Mulligan, Mark, Gaudinski, Martin R, Houser, Katherine V, Morabito, Kaitlyn M, Hu, Zonghui, Yamshchikov, Galina, Rothwell, Ro Shauna, Berkowitz, Nina, Mendoza, Floreliz, Saunders, Jamie G, Novik, Laura, Hendel, Cynthia S, Holman, LaSonji A, Gordon, Ingelise J, Cox, Josephine H, Edupuganti, Srilatha, McArthur, Monica A, Rouphael, Nadine G, Lyke, Kirsten E, Cummings, Ginny E, Sitar, Sandra, Bailer, Robert T, Foreman, Bryant M, Burgomaster, Katherine, Pelc, Rebecca S, Gordon, David N, DeMaso, Christina R, Dowd, Kimberly A, Laurencot, Carolyn, Schwartz, Richard M, Mascola, John R, Graham, Barney S, Pierson, Theodore C, Ledgerwood, Julie E, and Chen, Grace L

Published
2018
Full Text
View/download PDF

24. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection

Author

Lyke, Kirsten E., Ishizuka, Andrew S., Berry, Andrea A., Chakravarty, Sumana, DeZure, Adam, Enama, Mary E., James, Eric R., Billingsley, Peter F., Gunasekera, Anusha, Manoj, Anita, Li, Minglin, Ruben, Adam J., Li, Tao, Eappen, Abraham G., Stafford, Richard E., KC, Natasha, Murshedkar, Tooba, Mendoza, Floreliz H., Gordon, Ingelise J., Zephir, Kathryn L., Holman, LaSonji A., Plummer, Sarah H., Hendel, Cynthia S., Novik, Laura, Costner, Pamela J. M., Saunders, Jamie G., Berkowitz, Nina M., Flynn, Barbara J., Nason, Martha C., Garver, Lindsay S., Laurens, Matthew B., Plowe, Christopher V., Richie, Thomas L., Graham, Barney S., Roederer, Mario, Sim, B. Kim Lee, Ledgerwood, Julie E., Hoffman, Stephen L., and Seder, Robert A.

Published
2017

25. Immunogenomic profile at baseline predicts host susceptibility to clinical malaria

Author

Mbambo, Gillian, primary, Dwivedi, Ankit, additional, Ifeonu, Olukemi O., additional, Munro, James B., additional, Shrestha, Biraj, additional, Bromley, Robin E., additional, Hodges, Theresa, additional, Adkins, Ricky S., additional, Kouriba, Bourema, additional, Diarra, Issa, additional, Niangaly, Amadou, additional, Kone, Abdoulaye K., additional, Coulibaly, Drissa, additional, Traore, Karim, additional, Dolo, Amagana, additional, Thera, Mahamadou A., additional, Laurens, Matthew B., additional, Doumbo, Ogobara K., additional, Plowe, Christopher V., additional, Berry, Andrea A., additional, Travassos, Mark, additional, Lyke, Kirsten E., additional, and Silva, Joana C., additional

Published
2023
Full Text
View/download PDF

27. Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential

Author

Moser, Kara A., Drábek, Elliott F., Dwivedi, Ankit, Stucke, Emily M., Crabtree, Jonathan, Dara, Antoine, Shah, Zalak, Adams, Matthew, Li, Tao, Rodrigues, Priscila T., Koren, Sergey, Phillippy, Adam M., Munro, James B., Ouattara, Amed, Sparklin, Benjamin C., Dunning Hotopp, Julie C., Lyke, Kirsten E., Sadzewicz, Lisa, Tallon, Luke J., Spring, Michele D., Jongsakul, Krisada, Lon, Chanthap, Saunders, David L., Ferreira, Marcelo U., Nyunt, Myaing M., Laufer, Miriam K., Travassos, Mark A., Sauerwein, Robert W., Takala-Harrison, Shannon, Fraser, Claire M., Sim, B. Kim Lee, Hoffman, Stephen L., Plowe, Christopher V., and Silva, Joana C.

Published
2020
Full Text
View/download PDF

28. Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02A

Author

Berry, Andrea A., Gottlieb, Eric R., Kouriba, Bourema, Diarra, Issa, Thera, Mahamadou A., Dutta, Sheetij, Coulibaly, Drissa, Ouattara, Amed, Niangaly, Amadou, Kone, Abdoulaye K., Traore, Karim, Tolo, Youssouf, Mishcherkin, Vladimir, Soisson, Lorraine, Diggs, Carter L., Blackwelder, William C., Laurens, Matthew B., Sztein, Marcelo B., Doumbo, Ogobara K., Plowe, Christopher V., and Lyke, Kirsten E.

Published
2019
Full Text
View/download PDF

29. Strain-specific Plasmodium falciparum multifunctional CD4+ T cell cytokine expression in Malian children immunized with the FMP2.1/AS02A vaccine candidate

Author

Graves, Shawna F., Kouriba, Bourema, Diarra, Issa, Daou, Modibo, Niangaly, Amadou, Coulibaly, Drissa, Keita, Yamoussa, Laurens, Matthew B., Berry, Andrea A., Vekemans, Johan, Ripley Ballou, W., Lanar, David E., Dutta, Sheetij, Gray Heppner, D., Soisson, Lorraine, Diggs, Carter L., Thera, Mahamadou A., Doumbo, Ogobara K., Plowe, Christopher V., Sztein, Marcelo B., and Lyke, Kirsten E.

Published
2016
Full Text
View/download PDF

30. Hemoglobin C Trait Provides Protection From Clinical Falciparum Malaria in Malian Children

Author

Travassos, Mark A., Coulibaly, Drissa, Laurens, Matthew B., Dembélé, Ahmadou, Tolo, Youssouf, Koné, Abdoulaye K., Traoré, Karim, Niangaly, Amadou, Guindo, Aldiouma, Wu, Yukun, Berry, Andrea A., Jacob, Christopher G., Takala-Harrison, Shannon, Adams, Matthew, Shrestha, Biraj, Mu, Amy Z., Kouriba, Bourema, Lyke, Kirsten E., Diallo, Dapa A., Doumbo, Ogobara K., Plowe, Christopher V., and Thera, Mahamadou A.

Published
2015

31. Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Author

Mulligan, Mark J., Lyke, Kirsten E., Kitchin, Nicholas, Absalon, Judith, Gurtman, Alejandra, Lockhart, Stephen, Neuzil, Kathleen, Raabe, Vanessa, Bailey, Ruth, Swanson, Kena A., Li, Ping, Koury, Kenneth, Kalina, Warren, Cooper, David, Fontes-Garfias, Camila, Shi, Pei-Yong, Türeci, Özlem, Tompkins, Kristin R., Walsh, Edward E., Frenck, Robert, Falsey, Ann R., Dormitzer, Philip R., Gruber, William C., Şahin, Uğur, and Jansen, Kathrin U.

Published
2021
Full Text
View/download PDF

33. Malian children infected with Plasmodium ovale and Plasmodium falciparum display very similar gene expression profiles

Author

Tebben, Kieran, primary, Yirampo, Salif, additional, Coulibaly, Drissa, additional, Koné, Abdoulaye K., additional, Laurens, Matthew B., additional, Stucke, Emily M., additional, Dembélé, Ahmadou, additional, Tolo, Youssouf, additional, Traoré, Karim, additional, Niangaly, Amadou, additional, Berry, Andrea A., additional, Kouriba, Bourema, additional, Plowe, Christopher V., additional, Doumbo, Ogobara K., additional, Lyke, Kirsten E., additional, Takala-Harrison, Shannon, additional, Thera, Mahamadou A., additional, Travassos, Mark A., additional, and Serre, David, additional

Published
2023
Full Text
View/download PDF

34. Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial

Author

Lyke, Kirsten E, primary, Berry, Andrea A, additional, Mason, Kaitlin, additional, Idris, Azza H, additional, O'Callahan, Mark, additional, Happe, Myra, additional, Strom, Larisa, additional, Berkowitz, Nina M, additional, Guech, Mercy, additional, Hu, Zonghui, additional, Castro, Mike, additional, Basappa, Manjula, additional, Wang, Lu, additional, Low, Kwang, additional, Holman, LaSonji A, additional, Mendoza, Floreliz, additional, Gordon, Ingelise J, additional, Plummer, Sarah H, additional, Trofymenko, Olga, additional, Strauss, Kathleen S, additional, Joshi, Sudhaunshu, additional, Shrestha, Biraj, additional, Adams, Matthew, additional, Chagas, Andrezza Campos, additional, Murphy, Jittawadee R, additional, Stein, Judy, additional, Hickman, Somia, additional, McDougal, Andrew, additional, Lin, Bob, additional, Narpala, Sandeep R, additional, Vazquez, Sandra, additional, Serebryannyy, Leonid, additional, McDermott, Adrian, additional, Gaudinski, Martin R, additional, Capparelli, Edmund V, additional, Coates, Emily E, additional, Wu, Richard L, additional, Ledgerwood, Julie E, additional, Dropulic, Lesia K, additional, Seder, Robert A, additional, Young, Cheryl, additional, Boyce, Colleen, additional, Winkler, Jennifer, additional, Holian, Susan, additional, Greenberg, Nancy, additional, George, Shirley, additional, Kwon, Alyson, additional, Dorsey, Brenda, additional, Da Costa, Ana Raquel, additional, Witt, William, additional, Grays, Daryl, additional, Gapasin, Arren, additional, Bernal, Paula, additional, Floyd, Jeffrey, additional, Goldstein, Eric, additional, Howe, Leslie, additional, Lee, Myounghee, additional, Marron, Jennifer, additional, Brooks, Kelly, additional, Turek, Lisa, additional, Farley, Patricia, additional, Frels, Shantel, additional, Booth, Delores, additional, Gall, Jason, additional, Carlton, Kevin, additional, Albright, Gabriela, additional, Amharref, Nadia, additional, Atallah, Kandace, additional, Banappagari, Sashikanth, additional, Bastani, Niutish, additional, Blackstock, Daniel, additional, Boonyaratanakornkit, Bobby, additional, Carey, Elizabeth, additional, Charlton, Adam, additional, Chaudhuri, Rajoshi, additional, Caringal, Alegria M., additional, Chen, Mingzhong, additional, Chen, Peifeng, additional, Cheng, Wei, additional, Gowetski, Daniel, additional, Gulla, Krishana, additional, Hastings, Erica, additional, Horwitz, Joe, additional, Ivleva, Vera, additional, Kordella, Dan, additional, Kueltzo, Lisa A., additional, Lagler, Sara, additional, Le, Matt, additional, Lee, James, additional, Lei, Paula, additional, Li, Yile, additional, Nagy, Attila, additional, Patel, Aakash, additional, Runsewe, Peyi, additional, Shadrick, Will, additional, Shetty, Shamitha, additional, Wang, Hairong, additional, Webber, Calvin, additional, Vejzagic, Farah, additional, and Yang, Yoo-Jung, additional

Published
2023
Full Text
View/download PDF

35. A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria

Author

Sirima, Sodiomon B., primary, Ouédraogo, Alphonse, additional, Tiono, Alfred B., additional, Kaboré, Jean M., additional, Bougouma, Edith C., additional, Ouattara, Maurice S., additional, Kargougou, Désiré, additional, Diarra, Amidou, additional, Henry, Noelie, additional, Ouédraogo, Issa N., additional, Billingsley, Peter F., additional, Manoj, Anita, additional, Abebe, Yonas, additional, KC, Natasha, additional, Ruben, Adam, additional, Richie, Thomas L., additional, James, Eric R., additional, Joshi, Sudhaunshu, additional, Shrestha, Biraj, additional, Strauss, Kathy, additional, Lyke, Kirsten E., additional, Plowe, Christopher V., additional, Potter, Gail E., additional, Cox, Catherine, additional, Jones, Walter, additional, Sim, B. Kim Lee, additional, Hoffman, Stephen L., additional, and Laurens, Matthew B., additional

Published
2022
Full Text
View/download PDF

37. Increased levels of anti-PfCSP antibodies in post-pubertal females versus males immunized with PfSPZ Vaccine does not translate into increased protective efficacy

Author

KC, Natasha, primary, Church, L. W. Preston, additional, Riyahi, Pouria, additional, Chakravarty, Sumana, additional, Seder, Robert A., additional, Epstein, Judith E., additional, Lyke, Kirsten E., additional, Mordmüller, Benjamin, additional, Kremsner, Peter G., additional, Sissoko, Mahamadou S., additional, Healy, Sara, additional, Duffy, Patrick E., additional, Jongo, Said A., additional, Nchama, Vicente Urbano Nsue Ndong, additional, Abdulla, Salim, additional, Mpina, Maxmillian, additional, Sirima, Sodiomon B., additional, Laurens, Matthew B., additional, Steinhardt, Laura C., additional, Oneko, Martina, additional, Li, MingLin, additional, Murshedkar, Tooba, additional, Billingsley, Peter F., additional, Sim, B. Kim Lee, additional, Richie, Thomas L., additional, and Hoffman, Stephen L., additional

Published
2022
Full Text
View/download PDF

38. Malian children infected with Plasmodium ovale and Plasmodium falciparum display very similar gene expression profiles

Author

Tebben, Kieran, primary, Yirampo, Salif, additional, Coulibaly, Drissa, additional, Koné, Abdoulaye K., additional, Laurens, Matthew B., additional, Stucke, Emily M., additional, Dembélé, Ahmadou, additional, Tolo, Youssouf, additional, Traoré, Karim, additional, Niangaly, Amadou, additional, Berry, Andrea A., additional, Kouriba, Bourema, additional, Plowe, Christopher V., additional, Doumbo, Ogobara K, additional, Lyke, Kirsten E., additional, Takala-Harrison, Shannon, additional, Thera, Mahamadou A., additional, Travassos, Mark A., additional, and Serre, David, additional

Published
2022
Full Text
View/download PDF

39. Serologic and Cytokine Profiles of Children with Concurrent Cerebral Malaria and Severe Malarial Anemia Are Distinct from Other Subtypes of Severe Malaria

Author

Sobota, Rafal S., primary, Goron, Abby R., additional, Berry, Andrea A., additional, Bailey, Jason A., additional, Coulibaly, Drissa, additional, Adams, Matthew, additional, Kone, Abdoulaye K., additional, Kouriba, Bourema, additional, Doumbo, Ogobara K., additional, Sztein, Marcelo B., additional, Felgner, Philip L., additional, Plowe, Christopher V., additional, Lyke, Kirsten E., additional, Thera, Mahamadou A., additional, and Travassos, Mark A., additional

Published
2022
Full Text
View/download PDF

40. Seroreactivity to Plasmodium falciparum Erythrocyte Membrane Protein 1 Intracellular Domain in Malaria-Exposed Children and Adults

Author

Travassos, Mark A., Niangaly, Amadou, Bailey, Jason A., Ouattara, Amed, Coulibaly, Drissa, Laurens, Matthew B., Pablo, Jozelyn, Jasinskas, Algis, Nakajima-Sasaki, Rie, Berry, Andrea A., Takala-Harrison, Shannon, Kouriba, Bourema, Rowe, J. Alexandra, Lyke, Kirsten E., Doumbo, Ogobara K., Thera, Mahamadou A., Felgner, Philip L., and Plowe, Christopher V.

Published
2013
Full Text
View/download PDF

41. SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses

Author

Branche, Angela R., Rouphael, Nadine G., Diemert, David J., Falsey, Ann R., Losada, Cecilia, Baden, Lindsey R., Frey, Sharon E., Whitaker, Jennifer A., Little, Susan J., Anderson, Evan J., Walter, Emmanuel B., Novak, Richard M., Rupp, Richard, Jackson, Lisa A., Babu, Tara M., Kottkamp, Angelica C., Luetkemeyer, Anne F., Immergluck, Lilly C., Presti, Rachel M., Bäcker, Martín, Winokur, Patricia L., Mahgoub, Siham M., Goepfert, Paul A., Fusco, Dahlene N., Malkin, Elissa, Bethony, Jeffrey M., Walsh, Edward E., Graciaa, Daniel S., Samaha, Hady, Sherman, Amy C., Walsh, Stephen R., Abate, Getahun, Oikonomopoulou, Zacharoula, El Sahly, Hana M., Martin, Thomas C.S., Rostad, Christina A., Smith, Michael J., Ladner, Benjamin G., Porterfield, Laura, Dunstan, Maya, Wald, Anna, Davis, Tamia, Atmar, Robert L., Mulligan, Mark J., Lyke, Kirsten E., Posavad, Christine M., Meagher, Megan A., Stephens, David S., Neuzil, Kathleen M., Abebe, Kuleni, Hill, Heather, Albert, Jim, Lewis, Teri C., Giebeig, Lisa A., Eaton, Amanda, Netzl, Antonia, Wilks, Samuel H., Türeli, Sina, Makhene, Mamodikoe, Crandon, Sonja, Lee, Marina, Nayak, Seema U., Montefiori, David C., Makowski, Mat, Smith, Derek J., Roberts, Paul C., and Beigel, John H.

Subjects
Article
Abstract

BackgroundProtection from SARS-CoV-2 vaccines wanes over time and is compounded by emerging variants including Omicron subvariants. This study evaluated safety and immunogenicity of SARS-CoV-2 variant vaccines.MethodsThis phase 2 open-label, randomized trial enrolled healthy adults previously vaccinated with a SARS-CoV-2 primary series and a single boost. Eligible participants were randomized to one of six Moderna COVID19 mRNA vaccine arms (50µg dose): Prototype (mRNA-1273), Omicron BA.1+Beta (1 or 2 doses), Omicron BA.1+Delta, Omicron BA.1 monovalent, and Omicron BA.1+Prototype. Neutralization antibody titers (ID50) were assessed for D614G, Delta, Beta and Omicron BA.1 variants and Omicron BA.2.12.1 and BA.4/BA.5 subvariants 15 days after vaccination.ResultsFrom March 30 to May 6, 2022, 597 participants were randomized and vaccinated. Median age was 53 years, and 20% had a prior SARS-CoV-2 infection. All vaccines were safe and well-tolerated. Day 15 geometric mean titers (GMT) against D614G were similar across arms and ages, and higher with prior infection. For uninfected participants, Day 15 Omicron BA.1 GMTs were similar across Omicron-containing vaccine arms (3724-4561) and higher than Prototype (1,997 [95%CI:1,482-2,692]). The Omicron BA.1 monovalent and Omicron BA.1+Prototype vaccines induced a geometric mean ratio (GMR) to Prototype for Omicron BA.1 of 2.03 (97.5%CI:1.37-3.00) and 1.56 (97.5%CI:1.06-2.31), respectively. A subset of samples from uninfected participants in four arms were also tested in a different laboratory at Day 15 for neutralizing antibody titers to D614G and Omicron subvariants BA.1, BA.2.12.2 and BA.4/BA.5. Omicron BA.4/BA.5 GMTs were approximately one third BA.1 GMTs (Prototype 517 [95%CI:324-826] vs. 1503 [95%CI:949-2381]; Omicron BA.1+Beta 628 [95%CI:367-1,074] vs. 2125 [95%CI:1139-3965]; Omicron BA.1+Delta 765 [95%CI:443-1,322] vs. 2242 [95%CI:1218-4128] and Omicron BA.1+Prototype 635 [95%CI:447-903] vs. 1972 [95%CI:1337-2907).ConclusionsHigher Omicron BA.1 titers were observed with Omicron-containing vaccines compared to Prototype vaccine and titers against Omicron BA.4/BA.5 were lower than against BA.1 for all candidate vaccines.Clinicaltrials.govNCT05289037

Published
2022

42. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

Author

Ishizuka, Andrew S, Lyke, Kirsten E, DeZure, Adam, Berry, Andrea A, Richie, Thomas L, Mendoza, Floreliz H, Enama, Mary E, Gordon, Ingelise J, Chang, Lee-Jah, Sarwar, Uzma N, Zephir, Kathryn L, Holman, LaSonji A, James, Eric R, Billingsley, Peter F, Gunasekera, Anusha, Chakravarty, Sumana, Manoj, Anita, Li, MingLin, Ruben, Adam J, Li, Tao, Eappen, Abraham G, Stafford, Richard E, K C, Natasha, Murshedkar, Tooba, DeCederfelt, Hope, Plummer, Sarah H, Hendel, Cynthia S, Novik, Laura, Costner, Pamela J M, Saunders, Jamie G, Laurens, Matthew B, Plowe, Christopher V, Flynn, Barbara, Whalen, William R, Todd, J P, Noor, Jay, Rao, Srinivas, Sierra-Davidson, Kailan, Lynn, Geoffrey M, Epstein, Judith E, Kemp, Margaret A, Fahle, Gary A, Mikolajczak, Sebastian A, Fishbaugher, Matthew, Sack, Brandon K, Kappe, Stefan H I, Davidson, Silas A, Garver, Lindsey S, Björkström, Niklas K, Nason, Martha C, Graham, Barney S, Roederer, Mario, Sim, B Kim Lee, Hoffman, Stephen L, Ledgerwood, Julie E, and Seder, Robert A

Published
2016
Full Text
View/download PDF

43. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

Author

Lyke, Kirsten E., primary, Atmar, Robert L., additional, Islas, Clara Dominguez, additional, Posavad, Christine M., additional, Szydlo, Daniel, additional, Paul Chourdhury, Rahul, additional, Deming, Meagan E., additional, Eaton, Amanda, additional, Jackson, Lisa A., additional, Branche, Angela R., additional, El Sahly, Hana M., additional, Rostad, Christina A., additional, Martin, Judith M., additional, Johnston, Christine, additional, Rupp, Richard E., additional, Mulligan, Mark J., additional, Brady, Rebecca C., additional, Frenck, Robert W., additional, Bäcker, Martín, additional, Kottkamp, Angelica C., additional, Babu, Tara M., additional, Rajakumar, Kumaravel, additional, Edupuganti, Srilatha, additional, Dobrzynski, David, additional, Coler, Rhea N., additional, Archer, Janet I., additional, Crandon, Sonja, additional, Zemanek, Jillian A., additional, Brown, Elizabeth R., additional, Neuzil, Kathleen M., additional, Stephens, David S., additional, Post, Diane J., additional, Nayak, Seema U., additional, Suthar, Mehul S., additional, Roberts, Paul C., additional, Beigel, John H., additional, Montefiori, David C., additional, Husson, Jennifer S., additional, Price, Angie, additional, Whitaker, Jennifer A., additional, Keitel, Wendy A., additional, Falsey, Ann R., additional, Shannon, Ian, additional, Graciaa, Daniel, additional, Rouphael, Nadine, additional, Anderson, Evan J., additional, Kamidani, Satoshi, additional, Muniz, Gysella B., additional, Bhatnagar, Sonika, additional, Wald, Anna, additional, Berman, Megan, additional, Porterfield, Laura, additional, Stanford, Amber, additional, Dong, Jennifer Lee, additional, Carsons, Steven E., additional, Badillo, Diana, additional, Parker, Susan, additional, Dickey, Michelle, additional, Larsen, Sasha E., additional, Hural, John, additional, Ingersoll, Brian, additional, Lee, Marina, additional, Lai, Lilin, additional, Floyd, Katharine, additional, Ellis, Madison, additional, Moore, Kathryn M., additional, Manning, Kelly, additional, Foster, Stephanie L., additional, and Patel, Mit, additional

Published
2022
Full Text
View/download PDF

44. Transcriptional profiling of human Vδ1 T cells reveals a pathogen-driven adaptive differentiation program

Author

McMurray, Jack L., primary, von Borstel, Anouk, additional, Taher, Taher E., additional, Syrimi, Eleni, additional, Taylor, Graham S., additional, Sharif, Maria, additional, Rossjohn, Jamie, additional, Remmerswaal, Ester B.M., additional, Bemelman, Frederike J., additional, Vieira Braga, Felipe A., additional, Chen, Xi, additional, Teichmann, Sarah A., additional, Mohammed, Fiyaz, additional, Berry, Andrea A., additional, Lyke, Kirsten E., additional, Williamson, Kim C., additional, Stubbington, Michael J.T., additional, Davey, Martin S., additional, Willcox, Carrie R., additional, and Willcox, Benjamin E., additional

Published
2022
Full Text
View/download PDF

45. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

Author

Husson, Jennifer S., Price, Angie, Whitaker, Jennifer A., Keitel, Wendy A., Falsey, Ann R., Shannon, Ian, Graciaa, Daniel, Rouphael, Nadine, Anderson, Evan J., Kamidani, Satoshi, Muniz, Gysella B., Bhatnagar, Sonika, Wald, Anna, Berman, Megan, Porterfield, Laura, Stanford, Amber, Dong, Jennifer Lee, Carsons, Steven E., Badillo, Diana, Parker, Susan, Dickey, Michelle, Larsen, Sasha E., Hural, John, Ingersoll, Brian, Lee, Marina, Lai, Lilin, Floyd, Katharine, Ellis, Madison, Moore, Kathryn M., Manning, Kelly, Foster, Stephanie L., Patel, Mit, Lyke, Kirsten E., Atmar, Robert L., Islas, Clara Dominguez, Posavad, Christine M., Szydlo, Daniel, Paul Chourdhury, Rahul, Deming, Meagan E., Eaton, Amanda, Jackson, Lisa A., Branche, Angela R., El Sahly, Hana M., Rostad, Christina A., Martin, Judith M., Johnston, Christine, Rupp, Richard E., Mulligan, Mark J., Brady, Rebecca C., Frenck, Robert W., Jr., Bäcker, Martín, Kottkamp, Angelica C., Babu, Tara M., Rajakumar, Kumaravel, Edupuganti, Srilatha, Dobrzynski, David, Coler, Rhea N., Archer, Janet I., Crandon, Sonja, Zemanek, Jillian A., Brown, Elizabeth R., Neuzil, Kathleen M., Stephens, David S., Post, Diane J., Nayak, Seema U., Suthar, Mehul S., Roberts, Paul C., Beigel, John H., and Montefiori, David C.

Published
2022
Full Text
View/download PDF

46. Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine

Author

Seder, Robert A., Chang, Lee-Jah, Enama, Mary E., Zephir, Kathryn L., Sarwar, Uzma N., Gordon, Ingelise J., Holman, LaSonji A., James, Eric R., Billingsley, Peter F., Gunasekera, Anusha, Richman, Adam, Chakravarty, Sumana, Manoj, Anita, Velmurugan, Soundarapandian, Li, MingLin, Ruben, Adam J., Li, Tao, Eappen, Abraham G., Stafford, Richard E., Plummer, Sarah H., Hendel, Cynthia S., Novik, Laura, Costner, Pamela J. M., Mendoza, Floreliz H., Saunders, Jamie G., Nason, Martha C., Richardson, Jason H., Murphy, Jittawadee, Davidson, Silas A., Richie, Thomas L., Sedegah, Martha, Sutamihardja, Awalludin, Fahle, Gary A., Lyke, Kirsten E., Laurens, Matthew B., Roederer, Mario, Tewari, Kavita, Epstein, Judith E., Sim, B. Kim Lee, Ledgerwood, Julie E., Graham, Barney S., and Hoffman, Stephen L.

Published
2013
Full Text
View/download PDF

48. Tracking human migrations by the analysis of the distribution of HLA alleles, lineages and haplotypes in closed and open populations

Author

Vina, Marcelo A. Fernandez, Hollenbach, Jill A., Lyke, Kirsten E., Sztein, Marcelo B., Maiers, Martin, Klitz, William, Cano, Pedro, Mack, Steven, Single, Richard, Brautbar, Chaim, Israel, Shosahna, Raimondi, Eduardo, Khoriaty, Evelyne, Inati, Adlette, Andreani, Marco, Testi, Manuela, Moraes, Maria Elisa, Thomson, Glenys, Stastny, Peter, and Cao, Kai

Published
2012

49. SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Author

Pajon, Rolando, primary, Doria-Rose, Nicole A., additional, Shen, Xiaoying, additional, Schmidt, Stephen D., additional, O’Dell, Sijy, additional, McDanal, Charlene, additional, Feng, Wenhong, additional, Tong, Jin, additional, Eaton, Amanda, additional, Maglinao, Maha, additional, Tang, Haili, additional, Manning, Kelly E., additional, Edara, Venkata-Viswanadh, additional, Lai, Lilin, additional, Ellis, Madison, additional, Moore, Kathryn M., additional, Floyd, Katharine, additional, Foster, Stephanie L., additional, Posavad, Christine M., additional, Atmar, Robert L., additional, Lyke, Kirsten E., additional, Zhou, Tongqing, additional, Wang, Lingshu, additional, Zhang, Yi, additional, Gaudinski, Martin R., additional, Black, Walker P., additional, Gordon, Ingelise, additional, Guech, Mercy, additional, Ledgerwood, Julie E., additional, Misasi, John N., additional, Widge, Alicia, additional, Sullivan, Nancy J., additional, Roberts, Paul C., additional, Beigel, John H., additional, Korber, Bette, additional, Baden, Lindsey R., additional, El Sahly, Hana, additional, Chalkias, Spyros, additional, Zhou, Honghong, additional, Feng, Jing, additional, Girard, Bethany, additional, Das, Rituparna, additional, Aunins, Anne, additional, Edwards, Darin K., additional, Suthar, Mehul S., additional, Mascola, John R., additional, and Montefiori, David C., additional

Published
2022
Full Text
View/download PDF

50. Homologous and Heterologous Covid-19 Booster Vaccinations

Author

Atmar, Robert L., primary, Lyke, Kirsten E., additional, Deming, Meagan E., additional, Jackson, Lisa A., additional, Branche, Angela R., additional, El Sahly, Hana M., additional, Rostad, Christina A., additional, Martin, Judith M., additional, Johnston, Christine, additional, Rupp, Richard E., additional, Mulligan, Mark J., additional, Brady, Rebecca C., additional, Frenck, Robert W., additional, Bäcker, Martín, additional, Kottkamp, Angelica C., additional, Babu, Tara M., additional, Rajakumar, Kumaravel, additional, Edupuganti, Srilatha, additional, Dobrzynski, David, additional, Coler, Rhea N., additional, Posavad, Christine M., additional, Archer, Janet I., additional, Crandon, Sonja, additional, Nayak, Seema U., additional, Szydlo, Daniel, additional, Zemanek, Jillian A., additional, Dominguez Islas, Clara P., additional, Brown, Elizabeth R., additional, Suthar, Mehul S., additional, McElrath, M. Juliana, additional, McDermott, Adrian B., additional, O’Connell, Sarah E., additional, Montefiori, David C., additional, Eaton, Amanda, additional, Neuzil, Kathleen M., additional, Stephens, David S., additional, Roberts, Paul C., additional, and Beigel, John H., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results